Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Ann Surg. 2011 Aug;254(2):320-5. doi: 10.1097/SLA.0b013e31822238d8.
This study evaluates the significance of tumor involvement of the liver in early T-stage tumors and lymph node (LN) metastases on outcome after R0 resection of gallbladder cancer (GBCA).
A prospectively maintained database, supplemented with review of the medical record, was used to identify patients who underwent a complete (R0) resection for GBCA. All patients underwent definitive surgical treatment at the initial operation (1 stage) or after initial noncurative cholecystectomy (incidental tumors, 2 stage), including partial hepatectomy and portal LN dissection, with or without bile duct and/or adjacent organ resection. Clinicopathological variables, including TNM stage, histologic tumor involvement of liver (residual or direct extension in the GB fossa or discontiguous disease), and the total number of regional LNs assessed were analyzed for their association with outcome.
One hundred twenty-two patients were identified and analyzed. The median follow up period was 23 months. Liver and nodal involvement by GBCA were observed in 61 (50%) and 41(34%) patients, respectively. Among patients with T2 tumors (n = 53), 48 (91%) were incidental. Liver involvement was present in 26%, and this factor was associated with decreased recurrence-free (RFS) and disease-specific survival (DSS) compared with patients with T2 tumors without liver involvement (median RFS, 12 months vs. not reached, P = 0.004, median DSS 25 months versus not reached, P = 0.003); T1b tumors (n = 10) were not associated with liver involvement. The median total lymph node count (TLNC) was 3 (range 0-20). For the entire cohort, survival of patients classified as N0 based on TLNC < 6 was significantly worse than that of N0 patients based on TLNC ≥ 6 (median RFS, 22 months versus not reached, P < 0.001, median DSS 41 months versus not reached, P < 0.001). Liver involvement and TLNC remained significant prognostic factors in a multivariate model that included TNM stage.
Resection and histologic evaluation of at least 6 lymph nodes improves risk-stratification after resection of GBCA. Incidental T2 tumors are often associated with residual liver disease and should be reclassified to reflect the adverse outcome. The data suggests a need for standardized minimum requirements for adequate surgical treatment and pathological examination.
本研究评估了早期 T 期肿瘤和淋巴结(LN)转移对胆囊癌(GBCA)RO 切除术后结局的意义。
使用前瞻性维护的数据库,辅以病历审查,确定接受 GBCA 完全(RO)切除的患者。所有患者均在初次手术时(1 期)或初次非治愈性胆囊切除术(偶然肿瘤,2 期)后接受确定性手术治疗,包括部分肝切除术和门脉 LN 清扫术,伴有或不伴有胆管和/或相邻器官切除术。分析包括 TNM 分期、肝脏组织学肿瘤受累(GB 窝内残留或直接延伸或不连续疾病)以及评估的区域 LN 总数在内的临床病理变量与结局的关系。
确定并分析了 122 例患者。中位随访时间为 23 个月。61 例(50%)和 41 例(34%)患者分别存在 GBCA 肝和淋巴结受累。在 T2 肿瘤患者(n=53)中,48 例(91%)为偶然肿瘤。26%的患者存在肝受累,与无肝受累的 T2 肿瘤患者相比,肝受累与无复发生存(RFS)和疾病特异性生存(DSS)降低相关(中位 RFS,12 个月 vs. 未达到,P=0.004,中位 DSS 25 个月 vs. 未达到,P=0.003);T1b 肿瘤(n=10)与肝受累无关。总淋巴结计数(TLNC)的中位数为 3(范围 0-20)。对于整个队列,根据 TLNC<6 分类为 N0 的患者的生存明显差于根据 TLNC≥6 分类为 N0 的患者(中位 RFS,22 个月 vs. 未达到,P<0.001,中位 DSS 41 个月 vs. 未达到,P<0.001)。肝受累和 TLNC 在包括 TNM 分期在内的多变量模型中仍然是重要的预后因素。
切除和组织学评估至少 6 个淋巴结可改善 GBCA 切除后的风险分层。偶然的 T2 肿瘤常伴有残余肝疾病,应重新分类以反映不良结局。数据表明需要标准化充分手术治疗和病理检查的最低要求。